Loading company…
MxT Biotech develops microfluidic delivery technology and equipment for cell therapy production.
Founded in 2021 by CEO Aram Chung, MxT Biotech develops microfluidic-based systems for delivering intracellular substances and correcting genes, along with automated equipment for mass-producing cell therapeutics. Its Hydroporator platform delivers materials such as proteins, mRNA, plasmid DNA, nanoparticles, and CRISPR-Cas9 RNPs into primary cells. The company is based in Seoul, South Korea. In May 2022, it raised KRW 5 billion in Series A funding from BNK Venture Capital, DAYLI Partners, Hyundai Investment Partners, We Ventures Partners, and AJU IB Investment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in